Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 15, 2014, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $30,330,507.50.

Highlighted Stocks Traded by Insiders:

BioScrip (BIOS) - FREE Research Report

Jorden Yon, who is Director at BioScrip, bought 5,000 shares at $7.21 on May 15, 2014. Following this transaction, the Director owned 15,000 shares meaning that the stake was reduced by 50% with the 5,000-share transaction.

The shares most recently traded at $7.42, up $0.21, or 2.78% since the insider transaction.

The average volume for BioScrip has been 1.9 million shares per day over the past 30 days. BioScrip has a market cap of $492.3 million and is part of the health care sector and health services industry. Shares are down 3.24% year-to-date as of the close of trading on Thursday.

BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services, and PBM Services. Currently, there are 5 analysts who rate BioScrip a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIOS - FREE

TheStreet Quant Ratings

rates BioScrip as a

hold

. Among the primary strengths of the company is its robust revenue growth -- not just in the most recent periods but in previous quarters as well. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full

BioScrip Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hospira (HSP) - FREE Research Report

Bowles Barbara L, who is Director at Hospira, sold 2,000 shares at $47.77 on May 15, 2014. Following this transaction, the Director owned 26,219 shares meaning that the stake was reduced by 7.09% with the 2,000-share transaction.

The shares most recently traded at $47.65, down $0.12, or 0.25% since the insider transaction.

The average volume for Hospira has been 1.3 million shares per day over the past 30 days. Hospira has a market cap of $8.0 billion and is part of the health care sector and drugs industry. Shares are up 14.56% year-to-date as of the close of trading on Thursday.

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. The company has a P/E ratio of 58.8. Currently, there are no analysts who rate Hospira a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HSP - FREE

TheStreet Quant Ratings

rates Hospira as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Hospira Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Altisource Portfolio Solutions (ASPS) - FREE Research Report

Linn W Michael, who is Director at Altisource Portfolio Solutions, bought 1,000 shares at $106.64 on May 15, 2014. Following this transaction, the Director owned 3,519 shares meaning that the stake was reduced by 39.7% with the 1,000-share transaction.

The shares most recently traded at $105.94, down $0.70, or 0.67% since the insider transaction. Historical insider transactions for Altisource Portfolio Solutions go as follows:

  • 4-Week # shares bought: 3,000
  • 12-Week # shares bought: 3,000
  • 24-Week # shares bought: 3,000

The average volume for Altisource Portfolio Solutions has been 308,200 shares per day over the past 30 days. Altisource Portfolio Solutions has a market cap of $2.3 billion and is part of the services sector and diversified services industry. Shares are down 33.74% year-to-date as of the close of trading on Thursday.

Altisource Portfolio Solutions S.A. operates as a marketplace and transaction solutions provider for the real estate, mortgage, and consumer debt industries in the United States. The company has a P/E ratio of 18.1. Currently, there is 1 analyst who rates Altisource Portfolio Solutions a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASPS - FREE

TheStreet Quant Ratings

rates Altisource Portfolio Solutions as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Altisource Portfolio Solutions Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null